load-bearing capacity and, frequently, restricted movement. 5 Spinal cord compression is a medical emergency that can lead to paralysis. 5 In addition to the effect on patients' well-being, SREs also place a significant burden on healthcare systems. Previous studies have shown that, in particular, surgery to bone is associated with long inpatient stays in patients with solid tumours or MM. 3, 9 Several retrospective studies in the United States of America (USA) and Europe that included patients with MM demonstrated increased healthcare resource utilisation (HRU) and/or costs associated with SREs. 3, 4, [10] [11] [12] [13] Although these data provide some insight into the impact that SREs have on HRU by these patients, they may be limited by the scope and completeness of the available HRU data and by the use of codes (clinical and/or administrative) as proxies for diagnosis and resource use. Prospective data, collected from a broader European population, could provide more extensive, complete and robust information on the real-life use of healthcare resources in the treatment of SREs to better inform optimum approaches for patient management and healthcare planning.
A prospective, observational, multinational study was conducted to evaluate the HRU associated with SREs in patients with bone lesions secondary to prostate, breast or lung cancer and MM in Canada, Germany, Italy, Spain, the United Kingdom (UK) and the USA. Data on the HRU associated with SREs in breast cancer, lung cancer and prostate cancer in the four European countries (Germany, Italy, Spain and the UK) have been previously reported. [14] [15] [16] Here, we report the European data for patients with MM.
| ME THODS

| Patients
The methods used in this study have been described previously. 3 Eligible patients were aged 18 years or older with bone lesions that were secondary to MM and had a life expectancy of at least 6 months. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and to have experienced at least one SRE in the 97 days before signing informed consent or up to 7 days afterwards. 16 Patients were excluded from the study if they were enrolled in an investigational drug trial for treatment of bone lesions or prevention of SREs.
| Study design
This was a multicentre, prospective, observational study conducted in centres across Europe (Germany, Italy, Spain and the UK), Canada and the USA. Analysis by country and tumour type was prespecified in the protocol. This analysis reports only on data from the four European countries in patients with bone lesions secondary to MM. If radiation or surgery to bone was carried out as a result of another SRE (ie, treatment of a primary SRE, such as pathologic fracture), the investigator had the option of attributing HRU to the primary SRE. SREs determined to be secondary to a primary SRE were excluded from the analysis, as reported previously. 
| Statistical analysis
| Skeletal-related events
Eligible patients experienced a total of 321 SREs. Analysis of the raw SRE data (which included SREs secondary to primary SREs and was ultimately excluded from the final HRU analysis) showed that the event rate in this population of patients (who had all experienced an SRE) was consistent across Germany, Italy and Spain (2.2, 1.9 and 2.2 SREs per patient-year, respectively), but slightly higher in the UK (2.6 SREs per patient-year). In total, 281 of the 321 SREs were suitable for inclusion in the HRU analysis ( Figure 1 ). Overall, radiation to bone (38.1%) and pathologic fracture (34.5%) were the most common SREs; spinal cord compression was the least common, accounting for 10.7% of SREs. 
TA B L E 1 Baseline demographics and disease history
There were some differences observed in the pattern of SREs between countries ( Figure 1 Across all SREs, the most common facility types for inpatient stays were surgical units/wards and oncology units/wards, with general units/wards, radiation units/wards and "other" units/ wards also used frequently (Table S1 ). 
| Outpatient visits
Outpatient visits were also common across all SREs (Figure 4 ). Figure S1 ).
| Procedures performed
External beam radiation therapy was the most common procedure type, with a mean of 4.3 (95% confidence interval [CI], 3.41-5.10)
procedures per SRE ( Figure S2 ).
Overall, each SRE required a mean (SD) of 7.4 (6.9) procedures ( Figure 5 ). Radiation to bone and spinal cord compression were associated with the highest mean (SD) number of 
| Emergency room and home health visits, and nursing home/long-term care facility stays
No home health visits were required, and very few emergency room visits (2 per 100 SREs) were reported. No nursing home/long-term facility care stays associated with SREs were reported. 
F I G U R E 4 Proportion of
| D ISCUSS I ON
To the best of our knowledge, this is the first prospective study to investigate HRU associated with SREs secondary to bone lesions in patients with MM in Europe. In addition, this is the first study in which HRU was assigned to specific SREs by the investigators.
This ensured that HRU was included in the analysis only when it was considered, in the expert opinion of the investigators, to be directly related to the SRE and not to the underlying disease.
Patient characteristics at enrolment were broadly similar across the countries, although there was a tendency for better ECOG performance status in Germany than in the other countries. Overall, radiation to bone (38.1%) and pathologic fracture (34.5%) were the most common SREs, and spinal cord compression was the least common (10.7%). In Spain and the UK, spinal cord compression was reported considerably more often than in Germany and Italy; radiation to bone was reported about half as often. The proportion of patients who had previous treatment with bisphosphonates for the prevention of SREs was approximately 50% in Italy and Spain and considerably higher in Germany and the UK (over 80%). This variation could possibly reflect intercountry differences in patient management pathways; recruitment of patients in our study was according to predefined targets and enrolment criteria and may not fully reflect the distribution of SREs in the real-world setting. Therefore, more studies would be required to verify such differences.
In line with studies of prostate cancer, breast cancer and lung cancer, all SREs were associated with substantial HRU. [14] [15] [16] Inpatient stays were common (36.7% of SREs), at a rate similar to that previously reported for lung cancer (41.0%) 15 and higher than that reported for breast and prostate cancers (both 26.0%), 14, 16 with an average duration of stay of approximately 3 weeks. The reason for the differences in the proportions of SREs requiring an inpatient stay across tumour types cannot be firmly concluded from these analyses, but it may be due to the high incidence of comorbidities in patients with MM; patients with MM are often immunocompromised, with an increased risk of severe infection, while 20%-40% have renal impairment. 17, 18 Yet, interestingly, the proportion of patients with MM who discontinued the study (27.5%, primarily owing to death) was lower than for other cancer types: breast cancer, 36.3%; lung cancer, 69.6%; MM, 27.5%; and prostate cancer, 45.0% (data not published). These differences may reflect the longer survival times of patients with MM compared with patients with metastatic solid tumours and also any associated differences in disease status in these latter patients at the point of SRE development; for example, patients with prostate cancer were at an advanced stage, 14 whereas patients with MM frequently have bone disease at diagnosis, earlier in the disease course. 19 All SRE types were associated with hospitalisation and substantial lengths of inpatient stay. Compared with other tumour subtypes included in this observational study, the proportion of patients with MM and SREs requiring an inpatient stay varied considerably across SRE types. Surgery to bone, spinal cord compression and non-vertebral fracture were most likely to require inpatient stays, and radiation to bone was the least likely. Spinal cord compression represents a significant burden because it often requires hospitalisation and, in this study, was associated with the longest duration of inpatient care (nearly 6 weeks). In patients with MM, 50% of spinal cord compressions required hospitalisation. This is a smaller proportion than in patients with other cancer types (lung cancer, 80%; prostate cancer, 74%; breast cancer, 58%). [14] [15] [16] The reasons for this difference are unclear and are beyond the scope of this study, but a speculative explanation could be that the threshold to initiate imaging of the spine is much lower in patients with MM compared with other cancer types, possibly because there is great awareness of the propensity of MM to cause spinal cord compression. Indeed, such investigation is often a standard of care at diagnosis in patients with MM. Some between-country differences were noted in the duration of inpatient stay. Duration was longer in Italy and Spain than in Germany or the UK. Across all SREs, the most common facility types for inpatient stays were surgical units/wards and oncology units/ wards, with general units/wards, radiation units/wards and "other" units/wards also used frequently.
Outpatient visits were necessary for the majority of SREs (63.7%) and were most frequently required for radiation to bone (74.8%) and vertebral fracture (73.3%). In the UK, the mean number of outpatient visits required per SRE was less than one-third of that of the overall mean. This is probably owing to the fact that radiotherapy is predominantly an outpatient procedure in the UK, 20 unless other medical requirements necessitate an inpatient stay.
Nevertheless, the data presented here indicate that outpatient visits impose a considerable burden on healthcare resources in Europe, similar to findings reported for other cancer types in this study. 3, [14] [15] [16] This study has identified that almost every SRE required a procedure, and multiple procedures were common. Overall, a mean of 7.4 procedures per SRE was required. Most procedures were performed in an outpatient setting, and external beam radiation therapy was the most common type of procedure. Radiation to bone was associated with the highest number of procedures per SRE (11.4), which-coupled with the high number of outpatient visits for this procedure-makes it a major contributor to the burden that SREs place on healthcare systems. This is consistent with the findings of previous studies. [21] [22] [23] The high numbers of outpatient visits and procedures observed probably reflect the use of multiple fractions of radiotherapy. 16 Considering the differences in the characteristics of the patients enrolled, the relatively small sample size and any variations in clinical practices across the countries, overall, patterns of HRU were broadly consistent. However, in the UK, the numbers of outpatient visits, procedures overall and procedures per SRE were all substantially lower than in the other countries. Differences in clinical practice between the countries may help to explain this variation; for example, multiple-fraction radiation sessions are more commonplace in mainland Europe, while single-fraction radiation is used more often in the UK. 14 Also in the UK, radiotherapy is not necessarily available in all hospitals, so some patients may have to travel to alternative centres. 20 There are some limitations to this study, as previously reported by Hoefeler et al 3 The differences in baseline characteristics between countries and physician clinical practice may explain some of the heterogeneity in outcomes. The duration of follow-up for this study was shorter than planned (median of 5. 24 In patients with bone lesions due to solid tumours (excluding breast or prostate cancers) or MM, denosumab was non-inferior to zoledronic acid in prolonging the time to first on-study SRE. 25 In patients with newly diagnosed MM in a phase 3 study of denosumab (n = 859) and zoledronic acid (n = 859), denosumab was non-inferior to zoledronic acid (P = .01) in prolonging the time to first on-study SRE (hazards ratio [95% CI]: 0.98 [0.85-1.14]). 26 The timing of the initiation of treatment with agents that preserve bone in patients with MM is an issue that should be considered.
The International Myeloma Working Group (IMWG) recommends that bisphosphonates should be initiated in patients with MM, with or without detectable osteolytic bone lesions on conventional radiography. 27 The American Society of Clinical Oncology recommends that bone-targeted therapy should be considered in all patients with MM receiving first-line, antimyeloma therapy, regardless of the presence of osteolytic bone lesions on conventional radiography. 27 IMWG guidelines, published in 2017, for the optimal use of 18 fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in patients with MM, recommend this technique to provide an earlier evaluation of response to therapy compared with MRI scans. 28 It is therefore feasible that, with increased use of these imaging techniques to visualise the burden of myeloma disease, the number of patients who are eligible for treatment and hence the use of bone-preserving agents will increase and thus reduce the HRU associated with SREs in MM. The data reported here indicate that studies directly examining the impact of bisphosphonates and denosumab on SRE-associated HRU would be warranted.
| CON CLUS IONS
SREs secondary to bone lesions are frequently observed in patients with MM, with radiation to the bone and pathologic fracture being the most common. This study highlights that SREs in these patients are associated with substantial HRU across the four European countries. All types of SRE were associated with hospitalisation, multiple procedures and substantial periods of inpatient stay. Mean inpatient stay was shortest in Germany where both the proportion of patients with ECOG performance status of 2 and incidence of spinal cord compression were lowest. This is in addition to the impact that SREs have on patients' well-being, activities of daily life and ability to work. Initiating treatments that delay or prevent SREs will, therefore, help not only to reduce the healthcare burden and reduce costs, particularly associated with inpatient stay, but also to have a positive effect on the quality of life of patients. Consequently, physicians involved in the management of MM should initiate prompt treatment with agents that preserve bone.
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